Tilray Q1 net loss widens to $40 million; revenue rises 23% to $257.1 million
Bitget2026/10/08 11:04Tilray posted Q1 net revenue of USD 257.1 million, up 23% year over year. Net loss widened to USD 40 million, with net loss per share at USD 0.32. Gross profit climbed 35% to USD 77.5 million, while gross margin widened 3 percentage points to 30%. Beverage net revenue rose 82% to USD 101.5 million, and cannabis net revenue fell 13% to USD 56.1 million. Tilray reaffirmed FY27 adjusted EBITDA guidance of USD 68 million to USD 75 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tilray Brands Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006527), on October 08, 2026, and is solely responsible for the information contained therein.
- Tilray posted Q1 net revenue of USD 257.1 million, up 23% year over year.
- Net loss widened to USD 40 million, with net loss per share at USD 0.32.
- Gross profit climbed 35% to USD 77.5 million, while gross margin widened 3 percentage points to 30%.
- Beverage net revenue rose 82% to USD 101.5 million, and cannabis net revenue fell 13% to USD 56.1 million.
- Tilray reaffirmed FY27 adjusted EBITDA guidance of USD 68 million to USD 75 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
